Yuri Lee
About Yuri Lee
Yuri Lee is the WW Pricing and Access Execution Lead at Bristol-Myers Squibb, with over 20 years of experience in the pharmaceutical and healthcare industry, specializing in market access, health economics, and outcomes research.
Current Role at Bristol-Myers Squibb
Yuri Lee currently serves as the WW Pricing and Access Execution Lead for JKT and Intercon at Bristol-Myers Squibb. In this role, she focuses on developing and implementing strategies for pricing and market access across various international markets, ensuring that pharmaceutical products can reach a wide range of patients.
Previous Positions at Bristol-Myers Squibb
Before her current role, Yuri Lee held several key positions at Bristol-Myers Squibb. From 2014 to 2017, she worked as the WW Pricing Lead for the Intercon region based in New York. Prior to that, from 2013 to 2014, she was the Market Access and Operations Manager for the Intercontinental region. From 2011 to 2013, she served as the Market Access and HEOR Manager in Korea, focusing on health economics and outcomes research.
Experience at Other Pharmaceutical Companies
Yuri Lee's career in the pharmaceutical industry extends beyond Bristol-Myers Squibb. She worked at GSK as a PE and DM Manager from 2007 to 2011. Prior to that, she was a P and R Specialist at MSD Korea from 2005 to 2007. She also served as a JAPAC Regional Pricing Director at Amgen and as a Reviewer at the Health Insurance Review Agency.
Educational Background
Yuri Lee holds a Master's degree from Seoul National University, which she earned between 2008 and 2011. She also achieved her Bachelor's degree from Ewha Womans University, where she studied from 1999 to 2003. Her academic background complements her extensive professional experience, providing a solid foundation in both theoretical and applied aspects of health economics and market access.
Specializations and Expertise
With over 20 years of experience in the pharmaceutical and healthcare industry, Yuri Lee specializes in market access, health economics, and outcomes research (HEOR). She has played a key role in pricing and market access strategies for regions including Japan, Korea, and the Intercontinental region. Furthermore, she possesses a strong background in health policy and reimbursement strategies, and has proven expertise in navigating complex regulatory environments. She is noted for leading cross-functional teams to achieve strategic business objectives in the global pharmaceutical landscape.